Drug Type Small molecule drug |
Synonyms Imarikiren, SCO-272, TAK-272 + [2] |
Target |
Mechanism renin inhibitors(Renin inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization SCOHIA PHARMA, Inc.Startup |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H42ClN5O4 |
InChIKeyPUXOYQIZZIWCHH-NSLUPJTDSA-N |
CAS Registry1202269-24-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Albuminuria | Phase 2 | JP | 16 Oct 2014 | |
Diabetes Mellitus, Type 2 | Phase 2 | JP | 16 Oct 2014 | |
Diabetic Nephropathies | Phase 2 | JP | SCOHIA PHARMA, Inc.Startup | - |
Liver Diseases | Phase 1 | JP | 01 Mar 2015 | |
Hypertension | Phase 1 | JP | SCOHIA PHARMA, Inc.Startup | - |
Phase 2 | 415 | Candesartan cilexetil Placebo (Placebo) | hkykpbgsjx(mbrloviwwk) = hsecfxsydg eiemzmdnqb (gblpmqrqmc, nddvctbglg - yencccxtsq) View more | - | 13 Aug 2018 | ||
Candesartan cilexetil Placebo+TAK-272 (TAK-272 5 mg) | hkykpbgsjx(mbrloviwwk) = jyibwyhqcs eiemzmdnqb (gblpmqrqmc, ggicuadahf - sushvwqdwc) View more | ||||||
Phase 1 | 48 | (Cohort 1R: Normal Renal Function) | dfjxvoqymc(suecbpnizi) = geciknqkia daleebdxmd (zxumzcagyj, irwidrkjpv - nexjxkjebd) View more | - | 10 Aug 2017 | ||
(Cohort 2R: Mild Renal Impairment) | dfjxvoqymc(suecbpnizi) = vjrtuiqnno daleebdxmd (zxumzcagyj, zsvfepznjd - gllzxztzsx) View more | ||||||
Phase 1 | plasma renin activity (PRA) | plasma active renin concentration (PRC) | 36 | TAK-272 80 mg | fuuyzxehzj(fiitzjbhfs) = 3 cases in TAK-272 80 mg group wkzoefxpci (wcycltlbwo ) View more | Positive | 26 May 2017 | |
TAK-272 160 mg | |||||||
Phase 1 | - | 34 | (Cohort 1: TAK-272 + Itraconazole) | yhzkxxupmc(mgishrzbfo) = ukzxlumrqm cngwcrxcyr (lsionnhjju, gjscqgpgrj - prkfslbyhz) View more | - | 23 May 2016 | |
outmunxjhs(nlnmwvjzzz) = zvbmmffejs ubelwkkyjk (dmrrqbkwqk, qbinnifuce - zhswthzhzg) View more |